{"id":144796,"date":"2026-08-13T05:26:12","date_gmt":"2026-08-13T05:26:12","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/144796\/"},"modified":"2026-08-13T05:26:12","modified_gmt":"2026-08-13T05:26:12","slug":"novo-nordisk-ceo-concedes-eli-lillys-market-share-gains-as-stock-slumps","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/144796\/","title":{"rendered":"Novo Nordisk CEO Concedes Eli Lilly\u2019s Market-Share Gains as Stock Slumps"},"content":{"rendered":"<p>    <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/24D0E8008FFF139BC48787F4CA0D2E7B6074655D9D87C4550433800D04FA7446\/subgraphmysterio\/resizefit_w960;quality_80;format_webp\/https:%2F%2Fmedia.zenfs.com%2Fen%2Fbeincrypto_us_662%2F0209081c4954668c6413f2023b18e99a.jpg\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Photo by BeInCrypto\" height=\"540\" width=\"960\" class=\"yf-j98iil loader\"\/><\/a> Photo by BeInCrypto           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo Nordisk&#8217;s stock keeps falling even when the news is good, and CEO Mike Doustdar just admitted why. Eli Lilly is beating Novo at its own game.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Doustdar sat down with CNBC&#8217;s Jim Cramer this week to explain the disconnect. Novo, famous for its GLP-1 medication Ozempic, raised its full-year sales guidance on August 4, narrowing its projected annual decline from 8% to 3% at the midpoint. Investors sold anyway. NVO shares dropped roughly 6% that day.  <\/p>\n<p>            A Beat That Still Lost          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Doustdar walked through the math on air. Novo slashed prices on Ozempic and Wegovy last year to widen patient access, and volume hasn&#8217;t caught up yet to offset those cuts. He compared it to basic arithmetic. Halving a price means you need double the volume just to break even, and volume never doubles on day one.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><iframe loading=\"lazy\" title=\"Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer\" width=\"1200\" height=\"675\" src=\"https:\/\/www.youtube.com\/embed\/7CNVKFUnt6Y?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">That gap between falling average revenue per prescription and rising patient counts is exactly what has investors nervous. Novo&#8217;s obesity and diabetes drugs now make up around 90% of its business, compared to about 60% at Eli Lilly, leaving Novo more exposed to any pricing or competitive shock in that single category.  <\/p>\n<p>        Doustdar&#8217;s Concession          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Oral Wegovy sits at the center of this story. Novo launched the pill version of its weight-loss drug in January, and it quickly became one of the fastest-selling drugs in pharmaceutical history. Doctors have already written more than 5 million prescriptions for it, and 1.5 million patients now take it worldwide. That volume makes Novo&#8217;s stock reaction even harder to explain on the surface.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Cramer pressed him on why Eli Lilly&#8217;s stock rally has outrun Novo&#8217;s despite a less dominant pill. Doustdar didn&#8217;t dodge the question.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">&#8220;Eli Lilly has been gaining market share. And they&#8217;re more diversified than Novo Nordisk&#8230; there is no secret that Lilly has been quite successful actually in having volume uptake and market share uptake above and beyond Novo.&#8221;  <\/p>\n<p>    <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/968EC1C02961E9955B70BD66592F4C2C936E0824B8DAEF6CB715C36B0521D8B4\/subgraphmysterio\/resizefit_w960;quality_80;format_webp\/https:%2F%2Fmedia.zenfs.com%2Fen%2Fbeincrypto_us_662%2F0410ae2741cff321dd33f1e1aab66c01.png\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Despite Ozempic's success, Novo's stock is struggling.\" height=\"335\" width=\"960\" class=\"yf-j98iil loader\"\/><\/a> Despite Ozempic&#8217;s success, Novo&#8217;s stock is struggling. Image Source: Trading View           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">He argued Lilly&#8217;s ad campaign leans on an older, lower-dose version of Wegovy for comparison. Novo&#8217;s newer high-dose formulation matches Lilly&#8217;s efficacy, according to Doustdar. That dispute sits at the center of Novo&#8217;s lawsuit against Lilly over its advertising claims.  <\/p>\n<p>        The Pill Still Wins on Paper           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The stock slump hasn&#8217;t slowed the pill&#8217;s numbers. In Novo&#8217;s own trials, the pill cuts weight by 17%, against 12% for Lilly&#8217;s rival pill, though the two drugs haven&#8217;t faced off head-to-head. Doustdar called it the best product launch in pharmaceutical history, a claim that&#8217;s hard to dispute on volume alone.  <\/p>\n","protected":false},"excerpt":{"rendered":"Photo by BeInCrypto Novo Nordisk&#8217;s stock keeps falling even when the news is good, and CEO Mike Doustdar&hellip;\n","protected":false},"author":2,"featured_media":144797,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[276,2832,272],"class_list":["post-144796","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-eli-lilly","tag-mike-doustdar","tag-novo-nordisk"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117086544660592179","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/144796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=144796"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/144796\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/144797"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=144796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=144796"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=144796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}